PedAM

Pediatric Disease Annotations & Medicines


	hypokalemia

Disease ID	700
Disease	hypokalemia
Definition	Abnormally low potassium concentration in the blood. It may result from potassium loss by renal secretion or by the gastrointestinal route, as by vomiting or diarrhea. It may be manifested clinically by neuromuscular disorders ranging from weakness to paralysis, by electrocardiographic abnormalities (depression of the T wave and elevation of the U wave), by renal disease, and by gastrointestinal disorders. (Dorland, 27th ed)
Synonym	deficiency k deficiency potassium hypokalaemia hypokalaemia (disorder) hypokalaemic syndrome hypokalemia (disorder) hypokalemia [disease/finding] hypokalemias hypokalemic syndrome hypopotassaemia hypopotassaemia syndrome hypopotassemia hypopotassemia syndrome hypopotassemias k deficiency low blood potassium levels low potassium syndrome low serum potassium level low serum potassium level (finding) low serum potassium level - finding potassium deficiency potassium depletion syndrome hypokalemic
DOID	DOID:4500 DOID:13582
ICD10	ICD10CM:E87.6
UMLS	C0020621
MeSH	D007008 D011191
SNOMED-CT	SNOMEDCT_US_2016_09_01:43339004
Comorbidity	UMLS \| Disease \| Sentences' Count(Total Sentences:89) C0020538 \| hypertension \| 22 C0011991 \| diarrhea \| 7 C0001126 \| renal tubular acidosis \| 6 C0020428 \| aldosteronism \| 5 C0004775 \| bartter syndrome \| 4 C0024523 \| malabsorption \| 4 C0030443 \| periodic paralysis \| 4 C0162429 \| malnutrition \| 4 C1384514 \| primary aldosteronism \| 4 C0011880 \| diabetic ketoacidosis \| 4 C0020428 \| hyperaldosteronism \| 4 C0268450 \| gitelman's syndrome \| 4 C0018801 \| heart failure \| 3 C0020456 \| hyperglycemia \| 3 C0019151 \| hepatic encephalopathy \| 2 C0020550 \| hyperthyroidism \| 2 C0040156 \| thyrotoxicosis \| 2 C0745140 \| hyperthyroid \| 2 C1527336 \| sjogren's syndrome \| 2 C0042373 \| vascular disease \| 2 C0011860 \| type 2 diabetes \| 2 C0020598 \| hypoglycemia \| 2 C0018799 \| heart diseases \| 2 C0007222 \| cardiovascular disease \| 2 C0011991 \| diarrhoea \| 2 C0035078 \| renal failure \| 2 C0020459 \| hyperinsulinemia \| 2 C0155616 \| secondary hypertension \| 2 C0003125 \| anorexia nervosa \| 2 C0024523 \| intestinal malabsorption \| 2 C0020437 \| hypercalcemia \| 2 C0011847 \| diabetes \| 2 C0036992 \| short bowel syndrome \| 2 C0018799 \| heart disease \| 2 C0268450 \| gitelman syndrome \| 2 C0242363 \| pancreatic endocrine tumor \| 1 C0017160 \| gastroenteritis \| 1 C0238402 \| pycnodysostosis \| 1 C1565489 \| renal insufficiency \| 1 C0013395 \| indigestion \| 1 C0040100 \| thymoma \| 1 C0002878 \| hemolytic anemia \| 1 C0010481 \| cushing syndrome \| 1 C0037274 \| dermatoses \| 1 C0014038 \| encephalitis \| 1 C0342494 \| adrenal cortical hyperplasia \| 1 C0206686 \| adrenocortical carcinoma \| 1 C0221043 \| pseudohyperaldosteronism \| 1 C0021390 \| inflammatory bowel disease \| 1 C0009377 \| colonic pseudo-obstruction \| 1 C0011860 \| type 2 diabetes mellitus \| 1 C0238358 \| hypokalemic periodic paralysis \| 1 C0020502 \| hyperparathyroidism \| 1 C0206667 \| adrenal adenoma \| 1 C0001430 \| adenoma \| 1 C0015974 \| periodic fever \| 1 C0021831 \| bowel disease \| 1 C0021400 \| influenza \| 1 C0264716 \| chronic heart failure \| 1 C0029456 \| osteoporosis \| 1 C0235250 \| hyperemesis \| 1 C0162429 \| undernutrition \| 1 C0334684 \| renal adenoma \| 1 C0022661 \| end-stage kidney disease \| 1 C0004775 \| bartter's syndrome \| 1 C1621895 \| adrenal hyperplasia \| 1 C0022681 \| sponge kidney \| 1 C0013473 \| eating disorder \| 1 C0018802 \| congestive heart failure \| 1 C0020456 \| hyperglycaemia \| 1 C1384514 \| conn's syndrome \| 1 C0019202 \| wilson's disease \| 1 C0002871 \| anemia \| 1 C0001623 \| adrenal insufficiency \| 1 C0037998 \| splenic infarction \| 1 C0013473 \| eating disorders \| 1 C0010481 \| cushing's syndrome \| 1 C0004096 \| asthma \| 1 C0020450 \| hyperemesis gravidarum \| 1 C0033687 \| proteinuria \| 1 C0020540 \| malignant hypertension \| 1 C0024530 \| malaria \| 1 C0022658 \| renal disease \| 1 C0022658 \| kidney disease \| 1 C0022660 \| acute renal failure \| 1 C0022681 \| medullary sponge kidney \| 1 C0011570 \| depression \| 1 C0013182 \| drug hypersensitivity \| 1 C0010674 \| cystic fibrosis \| 1
Curated Gene	Entrez_id \| Symbol \| Resource(Total Genes:7) INS \| 3630 \| CTD_human POMC \| 5443 \| CTD_human AGT \| 183 \| CTD_human SST \| 6750 \| CTD_human NPPB \| 4879 \| CTD_human ADRB2 \| 154 \| CTD_human NR3C1 \| 2908 \| CTD_human
Inferring Gene	(Waiting for update.)
Text Mined Gene	Entrez_id \| Symbol \| Score \| Resource(Total Genes:164) 104940698 \| DALIR \| DISEASES 50865 \| HEBP1 \| DISEASES 7092 \| TLL1 \| DISEASES 3784 \| KCNQ1 \| DISEASES 6561 \| SLC13A1 \| DISEASES 359 \| AQP2 \| DISEASES 22798 \| LAMB4 \| DISEASES 1113 \| CHGA \| DISEASES 479 \| ATP12A \| DISEASES 6822 \| SULT2A1 \| DISEASES 5539 \| PPY \| DISEASES 2908 \| NR3C1 \| DISEASES 3769 \| KCNJ13 \| DISEASES 6549 \| SLC9A2 \| DISEASES 525 \| ATP6V1B1 \| DISEASES 3759 \| KCNJ2 \| DISEASES 6568 \| SLC17A1 \| DISEASES 65266 \| WNK4 \| DISEASES 53947 \| A4GALT \| DISEASES 3630 \| INS \| DISEASES 3741 \| KCNA5 \| DISEASES 10343 \| PKDREJ \| DISEASES 47 \| ACLY \| DISEASES 50617 \| ATP6V0A4 \| DISEASES 8864 \| PER2 \| DISEASES 3290 \| HSD11B1 \| DISEASES 3757 \| KCNH2 \| DISEASES 6558 \| SLC12A2 \| DISEASES 495 \| ATP4A \| DISEASES 8178 \| ELL \| DISEASES 25939 \| SAMHD1 \| DISEASES 23476 \| BRD4 \| DISEASES 23415 \| KCNH4 \| DISEASES 5443 \| POMC \| DISEASES 10686 \| CLDN16 \| DISEASES 3781 \| KCNN2 \| DISEASES 6550 \| SLC9A3 \| DISEASES 5172 \| SLC26A4 \| DISEASES 5286 \| PIK3C2A \| DISEASES 84920 \| ALG10 \| DISEASES 90527 \| DUOXA1 \| DISEASES 51458 \| RHCG \| DISEASES 79798 \| ARMC5 \| DISEASES 3930 \| LBR \| DISEASES 5972 \| REN \| DISEASES 6574 \| SLC20A1 \| DISEASES 55502 \| HES6 \| DISEASES 1956 \| EGFR \| DISEASES 1392 \| CRH \| DISEASES 114571 \| SLC22A9 \| DISEASES 5805 \| PTS \| DISEASES 80224 \| NUBPL \| DISEASES 23704 \| KCNE4 \| DISEASES 5741 \| PTH \| DISEASES 2697 \| GJA1 \| DISEASES 23250 \| ATP11A \| DISEASES 3773 \| KCNJ16 \| DISEASES 760 \| CA2 \| DISEASES 9073 \| CLDN8 \| DISEASES 6750 \| SST \| DISEASES 776 \| CACNA1D \| DISEASES 22808 \| MRAS \| DISEASES 9992 \| KCNE2 \| DISEASES 1636 \| ACE \| DISEASES 1584 \| CYP11B1 \| DISEASES 6006 \| RHCE \| DISEASES 84661 \| DPY30 \| DISEASES 389015 \| SLC9A4 \| DISEASES 476 \| ATP1A1 \| DISEASES 213 \| ALB \| DISEASES 2150 \| F2RL1 \| DISEASES 84889 \| SLC7A3 \| DISEASES 6340 \| SCNN1G \| DISEASES 5347 \| PLK1 \| DISEASES 4665 \| NAB2 \| DISEASES 55867 \| SLC22A11 \| DISEASES 3479 \| IGF1 \| DISEASES 54360 \| CYTL1 \| DISEASES 154 \| ADRB2 \| DISEASES 5122 \| PCSK1 \| DISEASES 115111 \| SLC26A7 \| DISEASES 144245 \| ALG10B \| DISEASES 10008 \| KCNE3 \| DISEASES 26249 \| KLHL3 \| DISEASES 65125 \| WNK1 \| DISEASES 354 \| KLK3 \| DISEASES 3291 \| HSD11B2 \| DISEASES 8630 \| HSD17B6 \| DISEASES 8490 \| RGS5 \| DISEASES 124590 \| USH1G \| DISEASES 6888 \| TALDO1 \| DISEASES 1585 \| CYP11B2 \| DISEASES 9622 \| KLK4 \| DISEASES 6524 \| SLC5A2 \| DISEASES 3768 \| KCNJ12 \| DISEASES 6331 \| SCN5A \| DISEASES 8971 \| H1FX \| DISEASES 2520 \| GAST \| DISEASES 3772 \| KCNJ15 \| DISEASES 796 \| CALCA \| DISEASES 1187 \| CLCNKA \| DISEASES 4221 \| MEN1 \| DISEASES 3753 \| KCNE1 \| DISEASES 1576 \| CYP3A4 \| DISEASES 554 \| AVPR2 \| DISEASES 3762 \| KCNJ5 \| DISEASES 4306 \| NR3C2 \| DISEASES 3770 \| KCNJ14 \| DISEASES 1528 \| CYB5A \| DISEASES 56479 \| KCNQ5 \| DISEASES 6338 \| SCNN1B \| DISEASES 1811 \| SLC26A3 \| DISEASES 797 \| CALCB \| DISEASES 27347 \| STK39 \| DISEASES 2695 \| GIP \| DISEASES 55503 \| TRPV6 \| DISEASES 8645 \| KCNK5 \| DISEASES 4151 \| MB \| DISEASES 140803 \| TRPM6 \| DISEASES 10861 \| SLC26A1 \| DISEASES 4514 \| MT-CO3 \| DISEASES 56259 \| CTNNBL1 \| DISEASES 779 \| CACNA1S \| DISEASES 54617 \| INO80 \| DISEASES 3775 \| KCNK1 \| DISEASES 7432 \| VIP \| DISEASES 481 \| ATP1B1 \| DISEASES 6446 \| SGK1 \| DISEASES 480 \| ATP1A4 \| DISEASES 3766 \| KCNJ10 \| DISEASES 57127 \| RHBG \| DISEASES 3283 \| HSD3B1 \| DISEASES 3284 \| HSD3B2 \| DISEASES 1586 \| CYP17A1 \| DISEASES 2556 \| GABRA3 \| DISEASES 7809 \| BSND \| DISEASES 27063 \| ANKRD1 \| DISEASES 7422 \| VEGFA \| DISEASES 1188 \| CLCNKB \| DISEASES 1184 \| CLCN5 \| DISEASES 1041 \| CDSN \| DISEASES 4878 \| NPPA \| DISEASES 8428 \| STK24 \| DISEASES 9576 \| SPAG6 \| DISEASES 551 \| AVP \| DISEASES 6557 \| SLC12A1 \| DISEASES 56341 \| PRMT8 \| DISEASES 3758 \| KCNJ1 \| DISEASES 57222 \| ERGIC1 \| DISEASES 23426 \| GRIP1 \| DISEASES 23327 \| NEDD4L \| DISEASES 3778 \| KCNMA1 \| DISEASES 2641 \| GCG \| DISEASES 6329 \| SCN4A \| DISEASES 6559 \| SLC12A3 \| DISEASES 9498 \| SLC4A8 \| DISEASES 1589 \| CYP21A2 \| DISEASES 846 \| CASR \| DISEASES 51312 \| SLC25A37 \| DISEASES 270 \| AMPD1 \| DISEASES 6230 \| RPS25 \| DISEASES 8972 \| MGAM \| DISEASES 567 \| B2M \| DISEASES 102723508 \| KANTR \| DISEASES
Locus	(Waiting for update.)

Disease ID	700
Disease	hypokalemia
Integrated Phenotype	(Waiting for update.)
Text Mined Phenotype	HPO \| Name \| Sentences' Count(Total Phenotypes:112) HP:0000822 \| Hypertension \| 23 HP:0001948 \| Alkalosis \| 22 HP:0200114 \| Metabolic alkalosis \| 20 HP:0003470 \| Inability to move \| 19 HP:0011675 \| Arrhythmias \| 18 HP:0001941 \| acidemia \| 13 HP:0001324 \| Muscular weakness \| 12 HP:0001942 \| Metabolic acidosis \| 12 HP:0003201 \| Rhabdomyolysis \| 11 HP:0002014 \| Diarrhea \| 7 HP:0002024 \| Intestinal malabsorption \| 6 HP:0002917 \| Low blood magnesium levels \| 6 HP:0001947 \| Renal tubular acidosis \| 6 HP:0002013 \| Emesis \| 5 HP:0004308 \| Ventricular arrhythmia \| 5 HP:0000859 \| Mineralocorticoid excess \| 5 HP:0002273 \| Tetraparesis \| 5 HP:0001649 \| Tachycardia \| 4 HP:0003768 \| Periodic paralysis \| 4 HP:0004395 \| Malnutrition \| 4 HP:0003074 \| High blood glucose \| 4 HP:0001953 \| Diabetic ketosis \| 4 HP:0001695 \| Cardiac arrest \| 4 HP:0004756 \| Ventricular tachycardia \| 3 HP:0012531 \| Pain \| 3 HP:0001945 \| Fever \| 3 HP:0002902 \| Hyponatremia \| 3 HP:0000103 \| Polyuria \| 3 HP:0004918 \| Hyperchloremic metabolic acidosis \| 3 HP:0003127 \| Low urine calcium levels \| 3 HP:0000083 \| Renal insufficiency \| 3 HP:0001635 \| Congestive heart failure \| 3 HP:0004934 \| Vascular calcification \| 2 HP:0002170 \| Intracranial hemorrhage \| 2 HP:0005977 \| Hypochloremic metabolic alkalosis \| 2 HP:0001664 \| Torsade de pointes \| 2 HP:0001714 \| Ventricular hypertrophy \| 2 HP:0002480 \| Hepatic encephalopathy \| 2 HP:0001399 \| Liver failure \| 2 HP:0003256 \| Coagulopathy \| 2 HP:0000836 \| Overactive thyroid \| 2 HP:0002664 \| Neoplasia \| 2 HP:0001712 \| Left ventricular hypertrophy \| 2 HP:0000842 \| Elevated insulin level \| 2 HP:0001974 \| Leukocytosis \| 2 HP:0001281 \| Tetany \| 2 HP:0000127 \| Salt wasting \| 2 HP:0002901 \| Hypocalcemia \| 2 HP:0001944 \| Dehydration \| 2 HP:0001943 \| Hypoglycemia \| 2 HP:0008341 \| Renal tubular acidosis, type I \| 2 HP:0003072 \| Hypercalcemia \| 2 HP:0002153 \| Elevated serum potassium levels \| 2 HP:0002039 \| Anorexia \| 2 HP:0002099 \| Asthma \| 1 HP:0001950 \| Respiratory alkalosis \| 1 HP:0000846 \| Hypoadrenalism \| 1 HP:0000093 \| Proteinuria \| 1 HP:0030252 \| Absence of mature B cells \| 1 HP:0011741 \| Secondary hyperaldosteronism \| 1 HP:0003351 \| Decreased plasma renin activity \| 1 HP:0001250 \| Seizures \| 1 HP:0000939 \| Osteoporosis \| 1 HP:0005943 \| Respiratory arrest \| 1 HP:0005110 \| Atrial fibrillation \| 1 HP:0012188 \| Hyperemesis gravidarum \| 1 HP:0000738 \| Sensory hallucination \| 1 HP:0002611 \| Cholestatic liver disease \| 1 HP:0002150 \| Hypercalcinuria \| 1 HP:0001657 \| Prolonged QT interval \| 1 HP:0006744 \| Adrenal carcinoma \| 1 HP:0000843 \| Hyperparathyroidism \| 1 HP:0001508 \| Weight faltering \| 1 HP:0000848 \| Hyperreninemia \| 1 HP:0011145 \| Symptomatic seizures \| 1 HP:0003196 \| Short nose \| 1 HP:0003113 \| Low blood chloride levels \| 1 HP:0002138 \| Subarachnoid hemorrhage \| 1 HP:0006682 \| Premature ventricular contractions \| 1 HP:0002383 \| Encephalitis \| 1 HP:0007185 \| Loss of consciousness \| 1 HP:0012735 \| Coughing \| 1 HP:0000969 \| Dropsy \| 1 HP:0001578 \| Hypercortisolism \| 1 HP:0002659 \| Increased tendency to fractures \| 1 HP:0002045 \| Abnormally low body temperature \| 1 HP:0000017 \| Nocturia \| 1 HP:0002315 \| Headaches \| 1 HP:0008221 \| Enlarged adrenal glands \| 1 HP:0000716 \| Depression \| 1 HP:0000815 \| Primary hypogonadism \| 1 HP:0000713 \| Agitation \| 1 HP:0002098 \| Respiratory distress \| 1 HP:0100522 \| Thymoma \| 1 HP:0001892 \| Bleeding diathesis \| 1 HP:0007340 \| Lower limb weakness \| 1 HP:0030731 \| Carcinoma \| 1 HP:0001903 \| Anemia \| 1 HP:0005086 \| Knee osteoarthritis \| 1 HP:0003394 \| Muscle cramps \| 1 HP:0012233 \| Intramuscular haematoma \| 1 HP:0005115 \| arrhythmias, Supraventricular \| 1 HP:0012272 \| Osborne waves \| 1 HP:0030405 \| Pancreatic endocrine tumor \| 1 HP:0001878 \| Haemolytic anaemia \| 1 HP:0000124 \| Renal tubular defect \| 1 HP:0001663 \| Ventricular fibrillation \| 1 HP:0002630 \| Fat malabsorption \| 1 HP:0000975 \| Increased sweating \| 1 HP:0001919 \| Acute renal failure \| 1 HP:0002028 \| Chronic diarrhea \| 1 HP:0001993 \| Ketoacidosis \| 1

Disease ID	700
Disease	hypokalemia
Manually Symptom	(Waiting for update.)
Text Mined Symptom	(Waiting for update.)

Manually Genotype(Total Text Mining Genotypes:0)
(Waiting for update.)

All Snps(Total Genotypes:0)
(Waiting for update.)

GWASdb Annotation(Total Genotypes:0)
(Waiting for update.)

GWASdb Snp Trait(Total Genotypes:0)
(Waiting for update.)

Mapped by lexical matching(Total Items:0)
(Waiting for update.)

Mapped by homologous gene(Total Items:0)
(Waiting for update.)

Chemical(Total Drugs:63)
CUI	ChemicalName	ChemicalID	CasRN	DiseaseName	DiseaseID	DirectEvidence	PubMedIDs
C0020621	acetaminophen	D000082	103-90-2	hypokalemia	MESH:D007008	marker/mechanism	12088358
C0020621	amikacin	D000583	37517-28-5	hypokalemia	MESH:D007008	marker/mechanism	19884751
C0020621	amiloride	D000584	2609-46-3	hypokalemia	MESH:D007008	marker/mechanism	7018361
C0020621	amiloride	D000584	2609-46-3	hypokalemia	MESH:D007008	therapeutic	10669191
C0020621	ampicillin	D000667	69-53-4	hypokalemia	MESH:D007008	marker/mechanism	326044
C0020621	atenolol	D001262	29122-68-7	hypokalemia	MESH:D007008	marker/mechanism	11332259
C0020621	atenolol	D001262	29122-68-7	hypokalemia	MESH:D007008	therapeutic	12795776
C0020621	atropine	D001285	51-55-8	hypokalemia	MESH:D007008	marker/mechanism	3168573
C0020621	bendroflumethiazide	D001539	73-48-3	hypokalemia	MESH:D007008	marker/mechanism	17452686
C0020621	betamethasone	D001623	378-44-9	hypokalemia	MESH:D007008	marker/mechanism	19249894
C0020621	bisoprolol	D017298	66722-44-9	hypokalemia	MESH:D007008	marker/mechanism	8098220
C0020621	bisoprolol	D017298	66722-44-9	hypokalemia	MESH:D007008	therapeutic	12795776
C0020621	caffeine	D002110	1958/8/2	hypokalemia	MESH:D007008	marker/mechanism	10337936
C0020621	capreomycin	D002207	11003-38-6	hypokalemia	MESH:D007008	marker/mechanism	15006956
C0020621	carbenicillin	D002228	4697-36-3	hypokalemia	MESH:D007008	marker/mechanism	1067752
C0020621	chloroquine	D002738	1954/5/7	hypokalemia	MESH:D007008	marker/mechanism	16142151
C0020621	chlorthalidone	D002752	77-36-1	hypokalemia	MESH:D007008	marker/mechanism	10818057
C0020621	clofazimine	D002991	2030-63-9	hypokalemia	MESH:D007008	marker/mechanism	16295502
C0020621	codeine	D003061	76-57-3	hypokalemia	MESH:D007008	marker/mechanism	15605674
C0020621	cyclophosphamide	D003520	50-18-0	hypokalemia	MESH:D007008	marker/mechanism	10637075
C0020621	cyclothiazide	C004639	2259-96-3	hypokalemia	MESH:D007008	marker/mechanism	7128662
C0020621	cisplatin	D002945	15663-27-1	hypokalemia	MESH:D007008	marker/mechanism	11219485
C0020621	dicloxacillin	D004009	3116-76-5	hypokalemia	MESH:D007008	marker/mechanism	12088358
C0020621	digoxin	D004077	20830-75-5	hypokalemia	MESH:D007008	marker/mechanism	1259829
C0020621	enalapril	D004656	75847-73-3	hypokalemia	MESH:D007008	therapeutic	1623802
C0020621	erythromycin	D004917	114-07-8	hypokalemia	MESH:D007008	marker/mechanism	9733356
C0020621	foscarnet	D017245	4428-95-9	hypokalemia	MESH:D007008	marker/mechanism	1335467
C0020621	haloperidol	D006220	52-86-8	hypokalemia	MESH:D007008	marker/mechanism	2735214
C0020621	ifosfamide	D007069	3778-73-2	hypokalemia	MESH:D007008	marker/mechanism	16174228
C0020621	indomethacin	D007213	53-86-1	hypokalemia	MESH:D007008	marker/mechanism	3727353
C0020621	lidocaine	D008012	137-58-6	hypokalemia	MESH:D007008	marker/mechanism	8669646
C0020621	liposomal amphotericin b	C068538	-	hypokalemia	MESH:D007008	marker/mechanism	18039077
C0020621	methotrexate	D008727	1959/5/2	hypokalemia	MESH:D007008	marker/mechanism	12721279
C0020621	metolazone	D008788	17560-51-9	hypokalemia	MESH:D007008	marker/mechanism	6860532
C0020621	mifepristone	D015735	84371-65-3	hypokalemia	MESH:D007008	marker/mechanism	19289534
C0020621	mitomycin	D016685	1950/7/7	hypokalemia	MESH:D007008	marker/mechanism	1339077
C0020621	morphine	D009020	57-27-2	hypokalemia	MESH:D007008	marker/mechanism	17303035
C0020621	nafcillin	D009254	147-52-4	hypokalemia	MESH:D007008	marker/mechanism	1067752
C0020621	nitroprusside	D009599	15078-28-1	hypokalemia	MESH:D007008	marker/mechanism	20339970
C0020621	norepinephrine	D009638	51-41-2	hypokalemia	MESH:D007008	marker/mechanism	8734244
C0020621	oxaliplatin	C030110	-	hypokalemia	MESH:D007008	marker/mechanism	20092386
C0020621	propranolol	D011433	525-66-6	hypokalemia	MESH:D007008	therapeutic	2600984
C0020621	pyrazinamide	D011718	98-96-4	hypokalemia	MESH:D007008	marker/mechanism	4340029
C0020621	quinine	D011803	130-95-0	hypokalemia	MESH:D007008	marker/mechanism	9517707
C0020621	rosiglitazone	C089730	-	hypokalemia	MESH:D007008	therapeutic	19656910
C0020621	sirolimus	D020123	53123-88-9	hypokalemia	MESH:D007008	marker/mechanism	10221490
C0020621	sotalol	D013015	3930-20-9	hypokalemia	MESH:D007008	marker/mechanism	9733356
C0020621	sotalol	D013015	3930-20-9	hypokalemia	MESH:D007008	therapeutic	1032269
C0020621	spironolactone	D013148	1952/1/7	hypokalemia	MESH:D007008	marker/mechanism	15811903
C0020621	spironolactone	D013148	1952/1/7	hypokalemia	MESH:D007008	therapeutic	10100081
C0020621	streptozocin	D013311	18883-66-4	hypokalemia	MESH:D007008	marker/mechanism	11219485
C0020621	tenofovir	D000068698	-	hypokalemia	MESH:D007008	marker/mechanism	16868451
C0020621	terfenadine	D016593	50679-08-8	hypokalemia	MESH:D007008	marker/mechanism	16722159
C0020621	theophylline	D013806	58-55-9	hypokalemia	MESH:D007008	marker/mechanism	18724532
C0020621	thiopental	D013874	76-75-5	hypokalemia	MESH:D007008	marker/mechanism	12209290
C0020621	timolol	D013999	26839-75-8	hypokalemia	MESH:D007008	therapeutic	238860
C0020621	triamterene	D014223	396-01-0	hypokalemia	MESH:D007008	marker/mechanism	3727353
C0020621	triamterene	D014223	396-01-0	hypokalemia	MESH:D007008	therapeutic	2209135
C0020621	valproic acid	D014635	99-66-1	hypokalemia	MESH:D007008	marker/mechanism	11891102
C0020621	vancomycin	D014640	1404-90-6	hypokalemia	MESH:D007008	marker/mechanism	17344665
C0020621	vinblastine	D014747	865-21-4	hypokalemia	MESH:D007008	marker/mechanism	3686684
C0020621	vincristine	D014750	-	hypokalemia	MESH:D007008	marker/mechanism	582354
C0020621	zolpidem	C049109	82626-48-0	hypokalemia	MESH:D007008	marker/mechanism	17092685

FDA approved drug and dosage information(Total Drugs:9)
DiseaseID	Drug_name	active_ingredients	strength	Dosage Form/Route	Marketing Status	TE code	RLD	RS
MESH:D007008	rapamune	sirolimus	1MG/ML	SOLUTION;ORAL	Prescription	None	Yes	Yes
MESH:D007008	rapamune	sirolimus	1MG	TABLET;ORAL	Prescription	AB	Yes	No
MESH:D007008	eloxatin	oxaliplatin	50MG/VIAL Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons	INJECTABLE;IV (INFUSION)	Discontinued	None	Yes	No
MESH:D007008	eloxatin	oxaliplatin	50MG/10ML (5MG/ML)	INJECTABLE;IV (INFUSION)	Prescription	AP	Yes	Yes
MESH:D007008	oxaliplatin	oxaliplatin	50MG/10ML (5MG/ML)	INJECTABLE;IV (INFUSION)	Prescription	AP	Yes	Yes
MESH:D007008	ofirmev	acetaminophen	1GM/100ML (10MG/ML)	SOLUTION;IV (INFUSION)	Prescription	AP	Yes	Yes
MESH:D007008	ofirmev	acetaminophen	1GM/100ML (10MG/ML)	SOLUTION;IV (INFUSION)	Prescription	AP	Yes	Yes
MESH:D007008	acetaminophen	acetaminophen	650MG	SUPPOSITORY;RECTAL	Over-the-counter	None	Yes	Yes
MESH:D007008	acetaminophen	acetaminophen	650MG	SUPPOSITORY;RECTAL	Over-the-counter	None	Yes	Yes

FDA labeling changes(Total Drugs:9)
DiseaseID	Pediatric_Labeling_Date	Trade_Name	Generic_Name_or_Proper_Name	Indications Studied	Label Changes Summary	Product Labeling	BPCA(B)	PREA(P)	BPCA(B) and PREA(P)	Pediatric Rule (R)	Sponsor	Pediatric Exclusivity Granted Date	NNPS
MESH:D007008	11/3/2005	rapamune	sirolimus	Prophylaxis of organ rejection in patients undergoing renal transplants	Safety and efficacy established in children 13 years or older judged to be at low to moderate immunologic risk Safety was assessed in a controlled clinical trial in pediatric (	Labeling	B	-	-	-	Wyeth	11/17/2004	FALSE'
MESH:D007008	11/3/2005	rapamune	sirolimus	Prophylaxis of organ rejection in patients undergoing renal transplants	Safety and efficacy established in children 13 years or older judged to be at low to moderate immunologic risk Safety was assessed in a controlled clinical trial in pediatric (	Labeling	B	-	-	-	Wyeth	11/17/2004	FALSE'
MESH:D007008	10/1/2007	eloxatin	oxaliplatin	Solid tumors	The effectiveness of oxaliplatin in children has not been established No significant activity observed in 2 Phase I and 2 Phase II trials in 159 patients ages 7 months to 22 years with solid tumors Information on clinical studies and AEs	Labeling	B	-	-	-	Sanofi-Aventis	09/27/2006	FALSE'
MESH:D007008	10/1/2007	eloxatin	oxaliplatin	Solid tumors	The effectiveness of oxaliplatin in children has not been established No significant activity observed in 2 Phase I and 2 Phase II trials in 159 patients ages 7 months to 22 years with solid tumors Information on clinical studies and AEs	Labeling	B	-	-	-	Sanofi-Aventis	09/27/2006	FALSE'
MESH:D007008	10/1/2007	eloxatin	oxaliplatin	Solid tumors	The effectiveness of oxaliplatin in children has not been established No significant activity observed in 2 Phase I and 2 Phase II trials in 159 patients ages 7 months to 22 years with solid tumors Information on clinical studies and AEs	Labeling	B	-	-	-	Sanofi-Aventis	09/27/2006	FALSE'
MESH:D007008	2/11/2010	ofirmev	acetaminophen	Management of mild-to-moderate pain, for the management of moderate-to-severe pain with adjunctive opioid analgesics, and for the reduction of fever	The safety and effectiveness of Ofirmev for the treatment of acute pain and fever in pediatric patients ages 2 years and older is supported by evidence from adequate and well-controlled studies of Ofirmev in adults. Additional safety and PK data was collected in 355 from premature neonates to adolescents. The effectiveness of Ofirmev for the treatment of acute pain and fever has not been studied in pediatric patients < 2 years of age.The PK exposure of Ofirmev observed in children and adolescents is similar to adults, but higher in neonates and infants. Dosing simulations from PK data in infants and neonates suggest that dose reductions of 33% in infants 1 month to < 2 years of age, and 50% in neonates up to 28 days, with a minimum dosing interval of 6 hours, will produce a PK exposure similar to that observed in children age 2 years and olderMost common adverse reactions in pediatric patients were nausea, vomiting, constipation, pruritus, agitation, and atelectasis.Information on dosing, clinical studies, adverse reactions and PK parametersNew dosage form and route of administration	Labeling	-	P	-	-	Cadence	-	FALSE'
MESH:D007008	01/27/2017	ofirmev	acetaminophen	Treatmeny of pain and fever in pediatric patients birth to 2 years	Treatment of pain Efficacy was not demonstrated in pediatric patients younger than 2 years in a double-blind, placebo-controlled study of 198 pediatric patients younger than 2 years. Pediatric patients less than 2 years of age, including neonates from 28 to 40 weeks gestational age at birth, were randomized to receive opioid plus acetaminophen or opioid plus placebo. No difference in analgesic effect of intravenous acetaminophen, measured by assessment of reduced need for additional opioid treatment for pain control, was observed. Treatment of fever The safety and effectiveness for the treatment of fever in pediatric patients, including premature neonates born at 32 weeks or greater gestation is supported by adequate and well-controlled studies of Ofirmev in adults, clinical studies in 244 pediatric patients 2 years and older, and safety and pharmacokinetic data from 239 patients younger than 2 years including neonates 32 weeks or greater gestational age. Information on dosing, clinical trials. Postmarketing study.	Labeling	-	-	B,P	-	Mallinckrodt	11/7/2016	FALSE
MESH:D007008	2/11/2010	ofirmev	acetaminophen	Management of mild-to-moderate pain, for the management of moderate-to-severe pain with adjunctive opioid analgesics, and for the reduction of fever	The safety and effectiveness of Ofirmev for the treatment of acute pain and fever in pediatric patients ages 2 years and older is supported by evidence from adequate and well-controlled studies of Ofirmev in adults. Additional safety and PK data was collected in 355 from premature neonates to adolescents. The effectiveness of Ofirmev for the treatment of acute pain and fever has not been studied in pediatric patients < 2 years of age.The PK exposure of Ofirmev observed in children and adolescents is similar to adults, but higher in neonates and infants. Dosing simulations from PK data in infants and neonates suggest that dose reductions of 33% in infants 1 month to < 2 years of age, and 50% in neonates up to 28 days, with a minimum dosing interval of 6 hours, will produce a PK exposure similar to that observed in children age 2 years and olderMost common adverse reactions in pediatric patients were nausea, vomiting, constipation, pruritus, agitation, and atelectasis.Information on dosing, clinical studies, adverse reactions and PK parametersNew dosage form and route of administration	Labeling	-	P	-	-	Cadence	-	FALSE'
MESH:D007008	01/27/2017	ofirmev	acetaminophen	Treatmeny of pain and fever in pediatric patients birth to 2 years	Treatment of pain Efficacy was not demonstrated in pediatric patients younger than 2 years in a double-blind, placebo-controlled study of 198 pediatric patients younger than 2 years. Pediatric patients less than 2 years of age, including neonates from 28 to 40 weeks gestational age at birth, were randomized to receive opioid plus acetaminophen or opioid plus placebo. No difference in analgesic effect of intravenous acetaminophen, measured by assessment of reduced need for additional opioid treatment for pain control, was observed. Treatment of fever The safety and effectiveness for the treatment of fever in pediatric patients, including premature neonates born at 32 weeks or greater gestation is supported by adequate and well-controlled studies of Ofirmev in adults, clinical studies in 244 pediatric patients 2 years and older, and safety and pharmacokinetic data from 239 patients younger than 2 years including neonates 32 weeks or greater gestational age. Information on dosing, clinical trials. Postmarketing study.	Labeling	-	-	B,P	-	Mallinckrodt	11/7/2016	FALSE